SK Capital Partners have entered into an agreement to sell Noramco, Extractas Biosciences, and Purisys of the Noramco Group to Siegfried Holding AG, a Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry.
Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals, a finished-dose-form CDMO in the United States and Canada with sterile-fill-finish and controlled substance production capabilities.
Aaron Davenport, Chairman of Noramco’s Board of Directors and Managing Director at SK Capital, said, “SK Capital is privileged to have supported the Noramco Group and its team. We are excited to continue to support Halo Pharmaceuticals and accelerate its next phase of growth with greater focus as a standalone platform.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!